.
MergerLinks Header Logo

Announced

Completed

ARCH Venture Partners and 8VC led a $750m Series B round in RESILIENCE.

Financials

Edit Data
Transaction Value£562m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private Equity

Single Bidder

biopharmaceutical company

Acquisition

Venture Capital

United States

Minority

Completed

Pharmaceuticals

Private

Friendly

Domestic

Synopsis

Edit

Investment firms ARCH Venture Partners and 8VC led a $750m Series B round in RESILIENCE, a biopharmaceutical company, with participation from GV and NEA. "Our aim with RESILIENCE is to improve manufacturing of breakthrough medicines so that they are more accessible to patients and to foster scientific innovation that makes new modalities of medicine possible," Rahul Singhvi, RESILIENCE Co-Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US